Calithera Biosciences Inc logo

CALA - Calithera Biosciences Inc Share Price

$4.54 -0.3  -5.6%

Last Trade - 30/03/20

Sector
Healthcare
Size
Small Cap
Market Cap £236.5m
Enterprise Value £109.8m
Revenue £n/a
Position in Universe 3066th / 6308
Bullish
Bearish
Unlock CALA Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CALA Revenue Unlock CALA Revenue

Net Income

CALA Net Income Unlock CALA Revenue

Normalised EPS

CALA Normalised EPS Unlock CALA Revenue

PE Ratio Range

CALA PE Ratio Range Unlock CALA Revenue

Dividend Yield Range

CALA Dividend Yield Range Unlock CALA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CALA EPS Forecasts Unlock CALA Revenue
Profile Summary

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated March 9, 2010
Public Since October 2, 2014
No. of Shareholders: 21
No. of Employees: 93
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 64,683,621
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CALA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CALA
Upcoming Events for CALA
Similar to CALA
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.